0.2900EUR0.00%Mkt Cap: 12.98M EURP/E: 14.50Last update: 2026-06-01
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap12.98M EUR
Enterprise Value11.27M EUR
Revenue (TTM)21.00K EUR
Gross Profit13.00K EUR
Net Income (TTM)830.00K EUR
Revenue/Share0.0000 EUR
Last Price0.2900 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees4
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINUS1512052002
Valuation
P/E (Trailing)14.50
P/E (Forward)0.45
PEG—
EV/EBITDA-7.42
EV/Revenue536.81
P/S618.14
P/B5.37
EPS (TTM)0.02
EPS (Forward)0.64
52W Range
0.160027% of range0.6500
52W High0.6500 EUR
52W Low0.1600 EUR
Profitability
Gross Margin61.90%
Oper. Margin30414.28%
EBITDA Margin0.00%
Profit Margin3952.38%
ROE34.06%
ROA19.31%
Growth
Revenue Growth-95.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.90M EUR
CapEx (TTM)—
FCF Margin-5038.69%
FCF Yield-8.15%
Net Debt-1.71M EUR
Net Debt/EBITDA1.12
Balance Sheet
Debt/Equity0.00
Current Ratio1.92
Quick Ratio1.38
Book Value/Sh0.0540 EUR
Cash/Share0.0380 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.44.76M
Float14.15M
Insiders10.78%
Institutions58.59%
Technical
SMA 500.3107 (-6.7%)
SMA 2000.2663 (+8.9%)
Beta1.19
S&P 52W Chg27.94%
Avg Vol (30d)14.12K
Avg Vol (10d)15.24K
Technical Indicators
RSI (14)45.4
MACD-0.0056
MACD Signal-0.0063
MACD Hist.+0.0007
BB Upper0.3211 EUR
BB Middle0.2960 EUR
BB Lower0.2710 EUR
BB Width16.92%
ATR (14)0.0170 EUR
Vol Ratio (20d)1.08x